{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:38Z","timestamp":1790837198344,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100312","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:10:08Z","timestamp":1638364208000},"page":"100312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study"],"prefix":"10.1016","volume":"6","author":[{"given":"L.","family":"Cerbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Combarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Geraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alves Costa Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Flippot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Khoudour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100312_bib1","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2021.100312_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"34","key":"10.1016\/j.esmoop.2021.100312_bib3","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100312_bib4","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100312_bib5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100312_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100312_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure\u2013response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100312_bib8","article-title":"\u201cTachyphylaxis\u201d","volume":"81","author":"Lehne","year":"2013"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100312_bib9","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10637-011-9764-8","article-title":"Sorafenib exposure decreases over time in patients with hepatocellular carcinoma","volume":"30","author":"Arrondeau","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2021.100312_bib10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","article-title":"Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis","volume":"17","author":"Boudou-Rouquette","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100312_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40262-016-0443-y","article-title":"Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients","volume":"56","author":"Yu","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100312_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/onco.13711","article-title":"The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma","volume":"26","author":"Rassy","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100312_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/jcph.526","article-title":"Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects","volume":"55","author":"Nguyen","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100312_bib15","doi-asserted-by":"crossref","first-page":"abstr 4561","DOI":"10.1200\/JCO.2021.39.15_suppl.4561","article-title":"Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100312_bib14","doi-asserted-by":"crossref","first-page":"102062","DOI":"10.1016\/j.ctrv.2020.102062","article-title":"Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: implications for patient care","volume":"89","author":"Castellano","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100312_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100312_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12032-018-1113-8","article-title":"Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma","volume":"35","author":"Igarashi","year":"2018","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"10.1016\/j.esmoop.2021.100312_bib18","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100312_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100312_bib20","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100312_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100312_bib22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2021.100312_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/fcp.12327","article-title":"Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study","volume":"32","author":"Cabel","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100312_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2020.09.030","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100312_bib25","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian Managed Access Program","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin Genitourin Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100274X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100274X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:22Z","timestamp":1761855922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292100274X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S205970292100274X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100312","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100312"}}